Registration Dossier
Registration Dossier
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 201-956-3 | CAS number: 89-98-5
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
Key value for chemical safety assessment
Additional information
In an experimental study of Rietveld et al. (1988) radiolabelled 14C-2-chlorobenzaldehyde was applied intravenously (25 µl/kg) or intraperitoneally (37.5 µl/kg) to male Wistar rats. Radioactivity was measured in blood, urine, faeces and exhaled air. The test item was rapidly and completely eliminated within 24 hours after intravenous and intraperitoneal application to rats. Excretion was mainly via urine (about 98%) and only small amounts were found in the faeces and exhaled air. Plasma elimination followed a bi-exponential fashion, the 14C half-life during the first elimination phase was 15.6 min.
Furthermore, mercapturic acids were isolated from the urines after continuous dosing with o-chlorobenzaldehyde. The structures of the methyl esters of the isolated substances were confirmed by NMR and mass spectra and were identified as the arylmethyl thioethers of N-acetylcysteine.
A second publication (Rietveld et al. 1986) revealed a benzylmercapturic acid excretion in the urine of 7.6 % of the dose after i.p. administration of 2-chlorobenzaldehyde to rats.
Additionally, Rietveld et al. (1988) showed that cutaneously administered 14C-2-chlorobenzaldehyde (75 µI/kg) was well absorbed by the skin of rats. The major portion of radioactivity was excreted in the urine. Urinary excretion of the radioactivity was found about 45% within the first 24 h post dosing: About 15% of the 75 µl/kg dose of 14C-2-chlorobenzaldehyde was found in the glasscup (semiocclusive cover) and on the skin. The principal metabolite in rat urine was 2-chlorohippuric acid. No part of the urinary radioactivity was present as parent compound and there was no evidence of storage in the skin or skin toxicity of 2-chlorobenzaldehyde following cutaneous application.
Altogether these publications show that 2-chlorobenzaldehyde is extensively biotransformed in mammalians after different routes of application and is mainly excreted in the urine as secondary metabolites in the first 24 hours after dosing.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
